💉 Enoxaparin (Clexane) Dose Calculator

Yes — Clexane is the international brand name for enoxaparin (marketed as Lovenox in the US), a low molecular weight heparin (LMWH). Generic enoxaparin products are also widely available; the weight-based dosing on this page applies regardless of brand or generic.

Treatment dosing (1 mg/kg twice daily) is used for confirmed or highly suspected VTE; prophylactic dosing (40 mg once daily) is a much lower, fixed dose used to prevent VTE in at-risk hospitalised patients — they are not interchangeable.

Enoxaparin is renally cleared, so reduced kidney function leads to drug accumulation and a higher bleeding risk — dosing is reduced at a CrCl below 30 mL/min, and some clinicians favour unfractionated heparin (more easily reversible and not renally dependent) in severe renal impairment.

Yes, it's commonly used for VTE prophylaxis and treatment in pregnancy, but dosing may need adjustment across trimesters as weight and clearance change — anti-Xa monitoring is often used to guide therapeutic dosing in pregnancy.

A minimum of 3 months for a first provoked VTE is standard, often longer (or indefinite) for unprovoked VTE, active cancer, or recurrent events — enoxaparin itself is frequently used only for the initial days-to-weeks before transitioning to an oral anticoagulant (a DOAC or warfarin) for the remainder of the course, per the specific indication and bleeding-risk assessment.

Treatment (DVT/PE): enoxaparin at treatment dose is typically given for at least 5 days, and until any bridged oral anticoagulant (e.g. warfarin) has reached a therapeutic INR on 2 consecutive days — in practice this is usually 5-10 days before stopping enoxaparin, though it may be continued much longer (weeks to months) as the sole anticoagulant when an oral option isn't suitable, such as in some cancer-associated thrombosis.

Prophylaxis (VTE prevention): duration depends heavily on the clinical setting — commonly 6-14 days for medical inpatients (or until fully mobile/discharged), around 7-10 days after general/major surgery, and considerably longer with extended prophylaxis after high-risk orthopaedic surgery (up to ~35 days after hip replacement, ~10-14 days after knee replacement) or major abdominal/pelvic cancer surgery (up to ~28 days). Always confirm the specific duration against the indication and current local protocol.

In patients on long-term warfarin who need a procedure, enoxaparin at treatment dose is typically substituted for warfarin in the days before and after surgery — started once the INR falls below the therapeutic range, stopped ~24 hours pre-procedure, and resumed post-operatively once haemostasis is adequate, until the INR is therapeutic again. Bridging is generally reserved for higher thromboembolic-risk patients (e.g. mechanical heart valves, recent VTE); routine bridging for most other indications is increasingly avoided given bleeding risk. DOACs, where used, usually don't need this kind of bridging due to their faster onset/offset.